Observational studyCancer reports (Hoboken, N.J.)2022

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Yuka Kawaji-Kanayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.